基于SPECT和PET的免疫成像技术研究进展

doi:10.7517/issn.1674-0475.210933

摘要/Abstract

摘要： 分子影像技术创新研究促进了体内免疫系统跟踪技术——免疫成像技术的发展，可实现对免疫细胞和免疫分子定位及其功能进行实时成像及无创可视化监控，协助评价免疫治疗的效果，并已成为免疫治疗中一个重要的新兴检测模块。目前，体内免疫成像技术的研究与应用仍处于初步阶段，本综述概述了近年来SPECT和PET成像方式用于免疫监测的研究进展，为未来免疫影像学新技术的发展和应用提供指导。

关键词: 免疫成像, 免疫治疗, 放射性标记, 单光子发射计算机体层摄影, 正电子发射断层成像

Abstract: The innovative molecular imaging technologies and tools have promoted the development of immune system tracking technology—immunoimaging technology, which can perform real-time non-invasive visualization of the existence and function of immune cells and immune molecules, thereby assisting in evaluating the effect of immunotherapy, and it has become an important detection module in immunotherapy. At present, the research and application of in vivo immunoimaging technology is still in a preliminary stage. This review summarized the research progress of single photon emission computed tomography and positron emission tomography imaging methods for immune monitoring in recent years, and provided guidance for the development and application of new immunoimaging technology in the future.

Key words: immunoimaging, immunotherapy, radiolabelling, single photon emission computed tomography (SPECT), positron emission tomography (PET)

张莉莉, 向韡, 刘超, 刘刚. 基于SPECT和PET的免疫成像技术研究进展[J]. 影像科学与光化学, 2022, 40(1): 1-10.

ZHANG Lili, XIANG Wei, LIU Chao, LIU Gang. Research Progress of Immunoimaging Technology Based on SPECT and PET[J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(1): 1-10.

参考文献

[1] Van De Donk P P, Kist De Ruijter L, Lub-De Hooge M N, et al. Molecular imaging biomarkers for immune checkpoint inhibitor therapy[J]. Theranostics, 2020, 10(4):1708-1718.
[2] Stanton S E, Eary J F, Marzbani E A, et al. Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo[J]. Journal for ImmunoTherapy of Cancer, 2016, 4:27.
[3] Telenga E D, van Der Bij W, de Vries E F J, et al. ⁹⁹mTc-HYNIC-IL-2 scintigraphy to detect acute rejection in lung transplantation patients:A proof-of-concept study[J]. EJNMMI Research, 2019, 9(1):41.
[4] Kristensen L K, Fröhlich C, Christensen C, et al. CD4⁺ and CD8a⁺ PET imaging predicts response to novel PD-1 checkpoint inhibitor:Studies of Sym021 in syngeneic mouse cancer models[J]. Theranostics, 2019, 9(26):8221-8238.
[5] Ahn S B, Lee S B, Singh T D, et al. Multimodality imaging of bone marrow-derived dendritic cell migration and antitumor immunity[J]. Translational Oncology, 2017, 10(2):262-270.
[6] Zhang M, Jiang H, Zhang R, et al. Near-infrared fluorescence-labeled anti-PD-L1-mAb for tumor imaging in human colorectal cancer xenografted mice[J]. Journal of Cellular Biochemistry, 2019, 120(6):10239-10247.
[7] Signore A, Capriotti G, Chianelli M, et al. Detection of insulitis by pancreatic scintigraphy with ⁹⁹mTc-labeled IL-2 and MRI in patients with LADA (Action LADA 10)[J]. Diabetes Care, 2015, 38(4):652-658.
[8] Witney T H, Blower P J. The chemical tool-kit for molecular imaging with radionuclides in the age of targeted and immune therapy[J]. Cancer Imaging, 2021, 21(1):18.
[9] Chapelin F, Capitini C M, Ahrens E T. Fluorine-19 MRI for detection and quantification of immune cell therapy for cancer[J]. Journal for Immunotherapy of Cancer, 2018, 6(1):105.
[10] Malviya G, Galli F, Sonni I, et al. Imaging T-lymphocytes in inflammatory diseases:A nuclear medicine approach[J]. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2014, 58(3):237-257.
[11] Malviya G, Nayak T, Gerdes C, et al. Isolation and (111)In-oxine labeling of murine NK cells for assessment of cell trafficking in orthotopic lung tumor model[J]. Molecular Pharmaceutics, 2016, 13(4):1329-1338.
[12] Wang X Y, Wang Y, Wu Q, et al. Feasibility study of ⁶⁸Ga-labeled CAR T cells for in vivo tracking using micro-positron emission tomography imaging[J]. Acta Pharmacologica Sinica, 2021, 42(5):824-831.
[13] Man F, Khan A A, Carrascal-Miniño A, et al. A kit formulation for the preparation of[⁸⁹Zr]Zr(oxinate)4 for PET cell tracking:White blood cell labelling and comparison with[¹¹¹In]In(oxinate)₃[J]. Nuclear Medicine and Biology, 2020, 90-91:31-40.
[14] Socan A, Petrik M, Kolenc P P, et al. On-cartridge preparation and evaluation of ⁶⁸Ga-, ⁸⁹Zr- and ⁶⁴Cu-precursors for cell radiolabelling[J]. Nuclear Medicine and Biology, 2019, 71:23-31.
[15] Zhu W, Xu Y, Jin R, et al. MRI tracking of dendritic cells loaded with superparamagnetic iron oxide nanoparticles[J]. Methods in Molecular Biology, 2020, 2126:107-116.
[16] Dulińska-Litewka J, Łazarczyk A, Hałubiec P, et al. Superparamagnetic iron oxide nanoparticles-current and prospective medical applications[J]. Materials (Basel, Switzerland), 2019, 12(4):617.
[17] Pektor S, Lawaczeck L, Tenzer S, et al. Characterization of activation induced
[18] F-FDG uptake in dendritic cells[J]. Nuklearmedizin, 2021, 60(2):90-98.
[18] Khanapur S, Yong F F, Hartimath S V, et al. An improved synthesis of N-(4-[¹⁸F]Fluorobenzoyl)-interleukin-2 for the preclinical PET imaging of tumour-infiltrating T-cells in CT26 and MC38 colon cancer models[J]. Molecules, 2021, 26(6):1728.
[19] van Der Veen E L, Suurs F V, Cleeren F, et al. Development and evaluation of interleukin-2-derived radiotracers for PET imaging of T Cells in mice[J]. Journal of Nuclear Medicine, 2020, 61(9):1355-1360.
[20] Nimmagadda S. Quantifying PD-L1 expression to monitor immune checkpoint therapy:Opportunities and challenges[J].Cancers (Basel), 2020, 12(11):3173.
[21] Verhoeff S R, van Den Heuvel M M, van Herpen C M L, et al. Programmed cell death-1/ligand-1 PET imaging:A novel tool to optimize immunotherapy?[J]. PET Clinics, 2020, 15(1):35-43.
[22] Mayer A T, Natarajan A, Gordon S R, et al. Practical immuno-PET radiotracer design considerations for human immune checkpoint imaging[J]. Journal of Nuclear Medicine, 2017, 58(4):538-546.
[23] Robu S, Richter A, Gosmann D, et al. Synthesis and preclinical evaluation of ⁶⁸Ga-labeled adnectin, ⁶⁸Ga-BMS-986192 as a PET agent for imaging PD-L1 expression[J]. Journal of Nuclear Medicine, 2021, 62(9):1228-1234.
[24] Shao F, Long Y, Ji H, et al. Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring[J]. Theranostics, 2021, 11(14):6800-6817.
[25] Keu K V, Witney T H, Yaghoubi S, et al. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma[J]. Science Translational Medicine, 2017, 9(373):eaag2196.
[26] Likar Y, Zurita J, Dobrenkov K, et al. A new pyrimidine-specific reporter gene:A mutated human deoxycytidine kinase suitable for PET during treatment with acycloguanosine-based cytotoxic drugs[J]. Journal of Nuclear Medicine, 2010, 51(9):1395-1403.
[27] Murty S, Labanieh L, Murty T, et al. PET reporter gene imaging and ganciclovir-mediated ablation of chimeric antigen receptor T cells in solid tumors[J]. Cancer Research, 2020, 80(21):4731-4740.
[28] Mccracken M N, Vatakis D N, Dixit D, et al. Noninvasive detection of tumor-infiltrating T cells by PET reporter imaging[J]. The Journal of Clinical Investigation, 2015, 125(5):1815-1826.
[29] Emami-Shahri N, Foster J, Kashani R, et al. Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells[J]. Nature Communications, 2018, 9(1):1081.
[30] Jacob J, Nadkarni S, Volpe A, et al. Spatiotemporal in vivo tracking of polyclonal human regulatory T cells (Tregs) reveals a role for innate immune cells in Treg transplant recruitment[J]. Molecular Therapy, Methods & Clinical Development, 2021, 20:324-336.
[31] Moroz M A, Zhang H, Lee J, et al. Comparative analysis of T cell imaging with human nuclear reporter genes[J]. Journal of Nuclear Medicine, 2015, 56(7):1055-1060.
[32] Perrin J, Capitao M, Mougin-Degraef M, et al. Cell tracking in cancer immunotherapy[J]. Frontiers in Medicine, 2020, 7:34.
[33] Krebs S, Ahad A, Carter L M, et al. Antibody with infinite affinity for in vivo tracking of genetically engineered lymphocytes[J]. Journal of Nuclear Medicine, 2018, 59(12):1894-1900.
[34] Hope T A, Goodman J Z, Allen I E, et al. Metaanalysis of ⁶⁸Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology[J]. Journal of Nuclear Medicine, 2019, 60(6):786-793.
[35] Minn I, Huss D J, Ahn H H, et al. Imaging CAR T cell therapy with PSMA-targeted positron emission tomography[J].Science Advances, 2019, 5(7):eaaw5096.
[36] Sier V Q, De Vries M R, Van Der Vorst J R, et al. Cell-based tracers as trojan horses for image-guided surgery[J].International Journal of Molecular Sciences,2021, 22(2):755.
[37] Larimer B M, Wehrenberg-Klee E, Caraballo A, et al. Quantitative CD3 PET imaging predicts tumor growth response to anti-CTLA-4 therapy[J]. Journal of Nuclear Medicine, 2016, 57(10):1607-1611.
[38] Lee D S W, Rojas O L, Gommerman J L. B cell depletion therapies in autoimmune disease:Advances and mechanistic insights[J]. Nature Reviews, Drug Discovery, 2021, 20(3):179-199.
[39] Stevens M Y, Cropper H C, Lucot K L, et al. Development of a CD19 PET tracer for detecting B cells in a mouse model of multiple sclerosis[J]. Journal of Neuroinflammation, 2020, 17(1):275.
[40] Kang L, Li C, Rosenkrans Z T, et al. Noninvasive evaluation of CD20 expression using ⁶⁴Cu-labeled F(ab')₂ fragments of obinutuzumab in lymphoma[J]. Journal of Nuclear Medicine, 2021, 62(3):372-378.
[41] Cao Q, Huang Q, Mohan C, et al. Small-animal PET/CT imaging of local and systemic immune response using ⁶⁴Cu-αCD11b[J]. Journal of Nuclear Medicine, 2019, 60(9):1317-1324.
[42] Alauddin M M, Khawli L A. Advances in immuno-PET for the detection of cancer and assessment of response to therapy[J]. Current Medicinal Chemistry, 2021, 28(4):647-672.
[43] Shaffer T, Natarajan A, Gambhir S S. PET imaging of TIGIT expression on tumor-infiltrating lymphocytes[J]. Clinical Cancer Research, 2021, 27(7):1932-1940.
[44] Park J W, Jung K H, Lee J H, et al. 89Zr anti-CD44 immuno-PET monitors CD44 expression on splenic myeloid cells and HT29 colon cancer cells[J]. Scientific Reports, 2021, 11(1):3876.
[45] Li D, Cheng S, Zou S, et al. Immuno-PET imaging of ⁸⁹Zr labeled anti-PD-L1 domain antibody[J]. Molecular Pharmaceutics, 2018, 15(4):1674-1681.
[46] Nedrow J R, Josefsson A, Park S, et al. Imaging of programmed cell death ligand 1:Impact of protein concentration on distribution of anti-PD-L1 SPECT agents in an immunocompetent murine model of melanoma[J]. Journal of Nuclear Medicine, 2017, 58(10):1560-1566.
[47] Natarajan A, Patel C B, Habte F, et al. Dosimetry prediction for clinical translation of ⁶⁴Cu-pembrolizumab immunoPET targeting human PD-1 expression[J]. Scientific Reports, 2018, 8(1):633.
[48] Li W, Wang Y, Rubins D, et al. PET/CT imaging of ⁸⁹Zr-N-sucDf-pembrolizumab in healthy cynomolgus monkeys[J]. Molecular Imaging and Biology, 2021, 23(2):250-259.
[49] Ehlerding E B, England C G, Majewski R L, et al. ImmunoPET imaging of CTLA-4 expression in mouse models of non-small cell lung cancer[J]. Molecular Pharmaceutics, 2017, 14(5):1782-1789.
[50] Ehlerding E B, Lee H J, Jiang D, et al. Antibody and fragment-based PET imaging of CTLA-4⁺ T-cells in humanized mouse models[J]. American Journal of Cancer Research, 2019, 9(1):53-63.
[51] Lee H J, Ehlerding E B, Cai W. Antibody-based tracers for PET/SPECT imaging of chronic inflammatory diseases[J]. Chembiochem, 2019, 20(4):422-436.
[52] Anzola L K, Galli F, Dierckx R A. SPECT radiopharmaceuticals for imaging chronic inflammatory diseases in the last decade[J]. The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2015, 59(2):197-213.
[53] Andrade P, van Aalst J, Bauwens M, et al. Radionuclide tumor necrosis factor-alpha activity in herniated lumbar disc correlates with severe leg pain[J]. Surgical Neurology International, 2020, 11:344.
[54] Dmochowska N, Tieu W, Keller M D, et al. Immuno-PET of innate immune markers CD11b and IL-1β detects inflammation in murine colitis[J]. Journal of Nuclear Medicine, 2019, 60(6):858-863.
[55] Jing H, Hettich M, Gaedicke S, et al. Combination treatment with hypofractionated radiotherapy plus IL-2/anti-IL-2 complexes and its theranostic evaluation[J]. Journal for Immunotherapy of Cancer, 2019, 7(1):55.